Recently , Innovent's innovative drug subsidiary, Innovent, announced that its new generation of anti-angiogenesis (anti-VEGF antibody) first-class biological new drug Enzeshu (generic name: Suvicitamab for injection) developed in China has been officially approved for marketing by the China National Medical Products Administration. Enzeshu is approved for the treatment of recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer in adults who have received no more than one systemic treatment after platinum resistance in combination with paclitaxel, liposome doxorubicin or topotecan.
It is reported that Enzeshu is the first targeted drug in my country to obtain indications for the entire population of platinum-resistant ovarian cancer, breaking the dilemma of limited treatment options in this field.
In recent years, the innovative transformation of the old pharmaceutical company Innovent Biologics has begun to show results. The company currently has 10 innovative drugs on the market, and 8 of them have been approved in the past five years. In 2024, the company's innovative drug revenue accounted for more than 74%. The approval of Enzeshu is expected to further consolidate the company's market position in the field of ovarian cancer.

https://www.nbd.com.cn/articles/2025-07-03/3932088.html